In the fifth and final part of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA shares what excites her most about the future of clinical technology.
ACT: What are some potential advancements in clinical technology that you are looking forward to in the future?
Easy: I did mention before One Home for Sites, and I am personally very excited about that, because I have the chance to work across the industry. I am currently working with many other vendors that people would consider competitors, we are working with sites, we are working with many sponsors, and it is about a very positive what can we do together? We are really focused on making the sites’ lives easier. To me, I am a very collaborative person, and I love that people are bought into this, and that we are really focusing on bringing everyone together. To me, that is certainly exciting personally, but I also get very excited about how we are as an industry getting better at reducing burden on sites, so there's a lot of focus on payments and how fast you can pay a site. I think that's brilliant, because of their cash flow. I think about our patients—everything we're doing is about their safety and how we increase it. To me, that is super exciting as a person, but even how we are starting to deploy AI (artificial intelligence) and LLMs (large language models) in a way that optimizes every part of a clinical trial, because we, clearly, all in this industry, want to be able to run studies faster, but safely, so that we are getting things to patients much faster. I, even just as a human—and I think that many people would think this too—I also start to then think about how this helps us with just general diagnosis of people's health. Clearly, a lot of this starts in clinical trials, but how we can move to a more proactive and less reactive kind of way of dealing with people's health, like accurate diagnostics and risk predictions, etc. For me, that actually is one of the driving things. I got very excited there.
